CLINICAL TRIALS PROFILE FOR BRIVANIB ALANINATE
✉ Email this page to a colleague
Clinical Trials for Brivanib alaninate
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00640471 ↗ | Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer | Completed | NCIC Clinical Trials Group | Phase 3 | RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving brivanib together with cetuximab is more effective than cetuximab alone in treating patients with metastatic colorectal cancer. PURPOSE: This randomized phase III trial is studying cetuximab to see how well it works compared with cetuximab given together with brivanib in treating patients with metastatic colorectal cancer. |
| NCT00798252 ↗ | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | Completed | Bristol-Myers Squibb | Phase 1 | To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors |
| NCT00888173 ↗ | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. |
| NCT00888173 ↗ | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | Completed | Gynecologic Oncology Group | Phase 2 | This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. |
| NCT01253668 ↗ | Brivanib Metastatic Renal Cell Carcinoma | Terminated | Abramson Cancer Center of the University of Pennsylvania | Phase 2 | This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imaging and molecular features of the tumors can be used to predict response. Approximately 30 people with advanced kidney cancer will be enrolled on this study at the University of Pennsylvania. |
| NCT01267253 ↗ | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Brivanib alaninate
Condition Name
Clinical Trial Locations for Brivanib alaninate
Trials by Country
Clinical Trial Progress for Brivanib alaninate
Clinical Trial Phase
Clinical Trial Sponsors for Brivanib alaninate
Sponsor Name
